Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Therapeutic area: Diabetes mellitus, type 2 This multi-part report includes: A1C glycated hemoglobin AE adverse event CI confidence interval CV cardiovascular CVOT cardiovascular outcomes trial DB double blind DPP-4 dipeptidyl peptidase-4 DULA dulaglutide eGFR estimated glomerular filtration rate EMA European Medicines Agency EMPA empagliflozin FDA Food and Drug Administration FPG fasting plasma glucose GLP-1 RA glucagon-like peptide-1 receptor agonist HRQoL health-related quality of life ITT intention-to-treat population LIRA liraglutide MET metformin NYHA New York Heart Association OAD oral antidiabetic PP per-protocol RCT randomized controlled trial SAE serious adverse event SC subcutaneous SD standard deviation SE standard error SEM semaglutide SGLT2 sodium-glucose cotransporter-2 SU sulfonylurea T2DM type 2 diabetes mellitus TEAE treatment-emergent adverse events TZD thiazolidinedione WDAE withdrawal due to adverse event An overview of the submission details for the drug under review is provided in Table 1
No membership fee or insurance requirement means you can prioritize kidney safety without financial barriers to regular check-ups
Lifestyle Habits: Certain lifestyle habits can also trigger diverticulitis flare-ups
Let's Stay in Touch
US$ 26.88
US$ 23.59
US$ 28.83
US$ 20.41
